Weber, M. S., Prod’homme, T., Youssef, S., Dunn, S. E., Steinman, L., & Zamvil, S. S. (2014). Neither T-helper type 2 nor Foxp3(+) regulatory T cells are necessary for therapeutic benefit of atorvastatin in treatment of central nervous system autoimmunity. BioMed Central.
Chicago Style citaatWeber, Martin S., Thomas Prod’homme, Sawsan Youssef, Shannon E. Dunn, Lawrence Steinman, en Scott S. Zamvil. Neither T-helper Type 2 nor Foxp3(+) Regulatory T Cells Are Necessary for Therapeutic Benefit of Atorvastatin in Treatment of Central Nervous System Autoimmunity. BioMed Central, 2014.
MLA citatieWeber, Martin S., et al. Neither T-helper Type 2 nor Foxp3(+) Regulatory T Cells Are Necessary for Therapeutic Benefit of Atorvastatin in Treatment of Central Nervous System Autoimmunity. BioMed Central, 2014.